Research Study

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy
Principal Investigator 
Sean Barbour

Overview

Body Locations and Systems 
Kidney Disease
ClinicalTrials.gov# 
NCT03301467
Status 
Recruiting
Study Start/End 
Mar 1, 2018 to Feb 28, 2019
Locations 
Diamond Health Care Centre, St. Paul's Hospital
Phone 
604-875-5950
Purpose of Study 

The purpose of this trial is to evaluate the effect of Avacopan treatment on renal disease activity in patients with complement component 3 glomerulopathy (C3G).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.